Second-line chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at different chemotherapy options for people with metastatic colorectal cancer that has stopped responding to first treatment. It aims to find which second-line approach works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that can be measured on scans.
- You have already had first-line chemotherapy and it stopped working, or you relapsed within 6 months of finishing adjuvant therapy.
- You are about to start your first second-line chemotherapy.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You have not taken any experimental drug in the last 4 weeks.
- You agree to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
This study tracks people with metastatic colorectal cancer who have already tried at least two standard treatments. It aims to collect real-world data on how well newer treatments work in later lines of therapy.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.